-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NDHEv0sjGC+g9bz3hX2t7c2ShLpa2Lxl3z2QS8NkCVLik497GALE6eHuCZ4hLcY1 pK+1EZBEcNOcC4xyR/0UuA== 0001254316-03-000021.txt : 20030804 0001254316-03-000021.hdr.sgml : 20030804 20030804201648 ACCESSION NUMBER: 0001254316-03-000021 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20030801 FILED AS OF DATE: 20030804 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SCHELLER RICHARD H CENTRAL INDEX KEY: 0001214133 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-09813 FILM NUMBER: 03822022 MAIL ADDRESS: STREET 1: C/O GENENTECH INC STREET 2: 1 DNA WAY MS 49 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080-4990 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GENENTECH INC CENTRAL INDEX KEY: 0000318771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 942347624 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 DNA WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-225-1000 MAIL ADDRESS: STREET 1: 1 DNA WAY STREET 2: . CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 edgardoc.xml PRIMARY DOCUMENT X0201 4 2003-08-01 0 0000318771 GENENTECH INC DNA 0001214133 SCHELLER RICHARD H C/O GENENTECH INC 1 DNA WAY MS 49 SOUTH SAN FRANCISCO CA 94080-4990 0 1 0 0 SR VICE PRESIDENT, RESEARCH Common Stock 2003-08-01 4 M 0 1354 41.8 A 1354 D Common Stock 2003-08-01 4 S 0 1354 80.12 D 0 D Common Stock 2003-08-01 4 M 0 2604 45.9 A 2604 D Common Stock 2003-08-01 4 S 0 2604 80.12 D 0 D Non-Qualified Stock Option (right to buy) 41.8 2003-08-01 4 M 0 1354 0 D 2001-09-26 2011-09-26 Common Stock 1354 35209 D Non-Qualified Stock Option (right to buy) 45.9 2003-08-01 4 M 0 2604 0 D 2001-03-13 2011-03-13 Common Stock 2604 49480 D This stock option vests over four years, with the first 25% of the shares vesting one year from the grant date and 75% of the shares vesting in equal monthly increments over the following three years. This option may be immediately exercisable with the consent of Genentech. /s/ Richard H. Scheller 2003-08-04 -----END PRIVACY-ENHANCED MESSAGE-----